John Gallon
Programme Lead - Organ Health Tagomics
Seminars
Wednesday 26th August 2026
LiquiPath™ – The world’s first cfDNA-based platform for multi-tissue drug safety monitoring
11:30 am
- The rapid expansion of ADC development is exposing the limitations of traditional approaches to safety assessment and monitoring
- Tissue-of-origin cfDNA provides a new window into treatment-induced injury
- One translational platform can support ADC safety from preclinical studies to patients, and better safety insight enables better ADC development decisions
